The Toll/IL-1R domain-containing adaptor protein SARM1 is expressed primarily in the brain, where it 14 mediates axonal degeneration. Additional roles for SARM1 in a number of other processes including TLR-15 signaling, viral infection, chemokine expression, and expression of the proapoptotic protein XAF1 have 16 also been described. Much of the supporting evidence for SARM1 function has been generated by 17 comparing WT C57BL/6 (B6) mice to SARM1-deficient mice backcrossed to the B6 background. Here we 18
Introduction 32
Sterile alpha and TIR motif containing 1 (SARM1) is an intracellular protein that is highly expressed in the 33 brain, and is comprised of a C-terminal Toll-interleukin receptor (TIR) domain, 2 central sterile alpha motif 34 (SAM) domains, and an N-terminal region containing multiple armadillio repeat motifs (ARMs) (1). SARM1 35 is essential in Wallerian degeneration -a neuronal cell death program involving MAPK signaling, influx of 36 calcium, and proteolysis of structural proteins resulting in axonal degeneration distal to the site of injury 37
(2, 3). Although the mechanism is not fully elucidated, SARM1 appears to be the master executioner in 38 this cascade (4). Mechanistic and structural studies suggest that the SARM1 TIR domain possesses 39 intrinsic NAD+ cleavage activity (5-7), which is regulated by JNK-mediated phosphorylation of leading to inhibition of mitochondrial respiration (8). 41 42
Because of the presence of the TIR domain, it was originally postulated that SARM1 would function in 43
TLR signaling similar to the other cytosolic TIR-domain containing proteins MYD88, MAL, TRIF, and 44
TRAM. In addition, the C.elegans and Drosophila orthologs tir-1 and dSARM (ect-4) appear to have roles 45 in immunity (9) (10) (11) . However, unlike the other four adaptor proteins, overexpression of SARM1 did not 46 lead to NF-κB or IRF3 activation, but rather inhibited TLR signaling (12). Overexpression studies have 47 supported a role for SARM1 in suppressing TLR responses, however studies in knockout mice have not 48
(1). Importantly, the SARM1 TIR domain appears to be evolutionarily ancestral to the mammalian TLR 49 adaptors because of its closer homology to bacterial TIR domains, suggesting that it may not function as 50 a TLR adapter (13, 14) . 51 52 SARM1 also appears to play a role in susceptibility to infections of the CNS. Two knockout strains for 53 SARM1 have been generated, one in the Ding lab here referred to as Sarm1 AD (1) and one in the 54
Diamond lab here referred to as Sarm1 MSD (15) . Sarm1 MSD mice are more susceptible to West Nile virus 55 infection (WNV), and produce less . In contrast, Sarm MSD mice are protected from lethal La 56 Crosse virus infection (LACV) (16) . Our previous studies found that Sarm1 AD mice were also protected 57 from lethal Vesicular Stomatitis virus (VSV) infection, and produced less cytokines and chemokines in the 58 brain (17) . A role for SARM1 has only been shown for infections in the CNS -we did not find differences 59
in the susceptibility of Sarm1 AD mice to M.tuberculosis, L. monocytogenes, or influenza virus infection 60 (17) . When Sarm1 AD macrophages were examined in response to a variety of TLR ligands no differences 61
were found in the production of TNF-α or CCL2 (1). However, SARM1 was reported to regulate CCL5 62 production in Sarm1 AD macrophages. This defect was specific to CCL5, occurred in response to TLR and 63 non-TLR stimuli, did not involve known signaling intermediates, but was associated with recruitment of 64
RNA pol II and transcription factors to the CCL5 locus (18) . A recent report also described both positive 65 and negative roles for SARM1 in inflammasome activation in Sarm1 AD mice, whereby SARM1 positively 66 regulates pyroptosis but negatively regulates IL-1b secretion (19) . 67 68 We previously reported upregulation of Xaf1 transcripts in the brains of uninfected and VSV-infected 69
Sarm1 AD mice compared to WT mice (17) . Zhu et al recently described a similar phenotype in Sarm MSD 70 mice, and reported that SARM1 modulates Xaf1 transcript expression and caspase-mediated cell death 71 (20) . X-linked inhibitor of apoptosis (XIAP)-associated factor (XAF1) is a proapoptotic gene that is epigenetically silenced in a broad range of human tumors. XAF1 appears to induce apoptosis 73 through a variety of mechanisms including binding and inhibiting XIAP (21), and binding p53 displacing 74 MDM2 leading to cell death (22) . Several isoforms of Xaf1 have been described, including full-length and 75 truncated forms. Full-length isoforms are frequently downregulated in human tumors, while truncated 76 isoforms are upregulated. Importantly, short forms have been reported to have dominant negative effects 77 (22, 23) . 78 79
Results 80 Macrophages derived from Sarm1 AD mice are defective in the production of Ccl3, Ccl4, and Ccl5 81
We stimulated bone marrow-derived macrophages with TLR ligands, or infected with viruses known to 82 activate the RLR sensing pathway and measured cytokine and chemokine production by ELISA. For this 83 purpose we compared WT C57BL/6J (B6) mice to SARM1-deficient mice generated in the Ding lab and 84 backcrossed 10 times to the B6 background, here referred to as Sarm1 AD (see Table I for background  85 details of the mice used in this study). We found that while TNF-α and IFN-α production were normal in 86
Sarm1 AD macrophages, CCL3 production was defective in response to all stimuli tested ( Fig 1A) . We next 87 asked if the defect in chemokine production occurred at the transcriptional level. Sarm1 AD macrophages 88 showed defects in the production of Ccl3, Ccl4, and Ccl5 mRNA in response to LPS stimulation at a 89 number of time points, but no defects in the production of Il1b or Ifnb1 (Fig 1B, top) , similar to results 90 reported for Ccl5 (18) . Given that we saw defects in chemokine production in response to a variety of TLR 91 stimuli, we next asked if signaling in response to TNF-α, which does not use the TLR adaptor proteins 92 MYD88 or TRIF, was defective in Sarm1 AD macrophages. Sarm1 AD macrophages again showed defects 93 in the production of Ccl3, Ccl4, and Ccl5 mRNA, but not Il1b or Ifnb1 (Fig 1B, We saw defects in the production of chemokines in Sarm1 AD macrophages in response to both LPS and 114 TNF-α stimulation, suggesting that SARM1 does not function at the level of the TLR-adapter proteins 115 MYD88 or TRIF. However, both LPS and TNF-α signaling activate the NF-κB and MAPK signaling 116 pathways (24, 25) . We therefore examined activation of these pathways in Sarm1 AD macrophages by 117 western blot. No differences were observed in the degradation of IκBα, or the phosphorylation of JNK, 118 ERK, or p38 in response to either LPS or TNF-α stimulation, suggesting that SARM1 does not regulate 119 induction of the NF-κB or MAPK pathways (Fig 2A and B) . LPS also activates PI3 kinase signaling 120 resulting in phosphorylation of Akt (26), however no differences in p-Akt levels were observed in Sarm1 AD 121 macrophages in response to LPS ( Fig 2C) . In addition, PLCγ-2 and intracellular calcium are required for 122 TLR4 endocytosis in response to LPS (27) . However, we again saw no differences in intracellular Ca 2+ 123 flux in Sarm1 AD macrophages in response to LPS or ATP stimulation ( Fig 2D) . 
131
The MIP and MCP chemokine family loci are within the Sarm1 129 congenic locus 132
Given that we saw defects only in Ccl3, Ccl4, and Ccl5 production but not in other cytokines, that the 133 defects occurred in response to a wide variety of stimuli, and that no defects in the induction pathways for 134 these cytokines could be found -we considered the possibility that the observed defect was due to the 135 genetic background of the knockout mouse rather than lack of SARM1 expression. The Sarm1 AD strain 136 was made by replacing exons 3-6 with a neomycin resistance gene in reverse orientation in 129 ES cells, 137 before backcrossing 10 times to the B6 background (1). The Ccl3, Ccl4, and Ccl5 genes and the Sarm1 138 gene are both located on mouse chromosome 11, and are separated by only ~5 Mb ( Fig 3A) . Despite 139 backcrossing 10 times, the probability of a region of 5 cM (~6.75 Mb for chromosome 11(28)) of 129 140 genetic material flanking both sides of the knockout gene is 0.63, making it likely that the chemokine 141 locus in Sarm1 AD mice is of 129 origin. In order to check the genetic background of genes proximal to 142 Sarm1, we sequenced two SNPs in the Ccl5 gene that differ between the 129 and B6 strains, which 143 confirmed that the Ccl5 locus of the Sarm1 AD strain is derived from the 129 strain ( Fig 3B) . 144 145
We next asked whether the production of other cytokines and chemokines located on different 146 chromosomes was different between WT and Sarm1 AD macrophages. We again saw differences in the 147 production of Ccl3, Ccl4, and Ccl5 mRNA, but we failed to find significant differences between other 148 cytokines or chemokines in different chromosomal locations ( Fig 3C) . The MCP chemokine region falls 149 between the Sarm1 gene and the MIP chemokine region, and is therefore of 129 genetic origin, however 150 no differences in the induction of Ccl1, Ccl2, or Ccl7 were observed. Il12b, which is also located on 151 chromosome 11, showed increased production in the Sarm1 AD strain. In addition to induced conditions 152 ( Fig 3D, top) , we also observed differences in the basal expression of Ccl3, Ccl4, and Ccl5 mRNA 153 between WT, Sarm1 +/AD , and Sarm1 AD/AD macrophages in the absence of stimulation ( Fig 3D, bottom) , 154 supporting an intrinsic difference between the strains. 155 156 157 
163

SARM1 knockdown and overexpression fail to regulate Ccl3, Ccl4, and Ccl5 levels 164
We next examined the role of SARM1 expression on chemokine production in a cell line, lacking the 165 confounding genetic background of the Sarm1 AD mouse strain. We first examined Sarm1 expression in 166 the mouse macrophage cell line RAW264.7 expressing a control V5 epitope tag (RAW-V5). We found 167 very low levels of Sarm1 mRNA expression, making knockdown efficiency difficult to access ( Fig 4A, left) . 168
This is in agreement with reports suggesting very low or no expression in mouse macrophages (1, 15) . 169
Upon treatment with LPS, no differences in Ccl4 induction were found with knockdown ( Fig 4A, right) . In 170 order to determine knockdown efficiency, we repeated the experiment in RAW264.7 cells overexpressing 171 V5-tagged SARM1 (RAW-SARM1-V5). Under these conditions, Sarm1 mRNA was detectable, and 172 siSARM1-1 and siSARM1-3 reduced transcript expression by 10x and 7x, respectively, confirming 173 knockdown ( Fig 4B, left) . Western blot for Sarm1-V5 expression revealed siSARM1-1 and siSARM1-3 174 reduced protein levels by 40% and 30%, respectively ( Fig 4C and S1) . The low knockdown efficiency is 175 likely due to high SARM1 expression from the CMV promoter, but nonetheless confirms the efficacy of the 176 siRNAs. However, upon LPS stimulation, again no differences in Ccl4 mRNA induction were detectable in 177 RAW-SARM1-V5 cells (Fig 4B, right) . We next performed knockdown in macrophages from WT and 178
Sarm1 AD mice. We were unable to detect Sarm1 mRNA expression in macrophages, and no reliable 179
antibodies are available (1, 15, 17, 18) , so we could not access knockdown efficiency. We again found 180 that basal levels of Ccl4 mRNA were reduced in Sarm1 AD macrophages compared to WT macrophages, 181 however siRNA treatment of WT macrophages failed to downregulate Ccl4 levels ( Fig 4D) . Lastly, we 182 determined whether overexpression of SARM1 in RAW cells modulated chemokine induction in response 183
to LPS. As shown in Figure 4E , no differences in chemokine levels were observed upon overexpression 184 of SARM1. The limited chemokine defects, lack of signaling defects, and lack of support from knockdown 185 or overexpression, as well as the close proximity of the Ccl3, Ccl4, and Ccl5 genes to the Sarm1 gene 186 makes it likely that the congenic interval rather than SARM1 protein expression contributes to differences 187 in basal and induced levels of Ccl3, Ccl4, and Ccl5 between WT and Sarm1 AD mice. 188 189 
196
Sarm1 CRISPR knockout mice on a pure B6 background show no macrophage chemokine defects 197
In order to formally exclude a role for SARM1 in chemokine induction, we generated new knockout mouse 198 strains using CRISPR-mediated genome engineering on a pure B6 background. A high-scoring guide 199 sequence that was unlikely to produce off-target cleavage was located in exon 1 of the Sarm1 gene (29). 200
This guide sequence was cloned into the pSpCas9(BB)-2A-GFP vector and injected into one-cell stage 201 C57BL/6J embryos. Resulting pups were characterized at the Sarm1 locus, as well as at potential off-202 target sites. Two knockout alleles were generated using this approach, termed Sarm1 AGS3 and 203
Sarm1 AGS12 . The Sarm1 AGS3 allele is a 62 b.p. deletion resulting in a frameshift and a 38 a.a. product; the 204 Sarm1 AGS12 allele is a 13 b.p. deletion resulting in a frameshift and a 74 a.a. product (Table II and Fig  205  S2A ). The 62 b.p. deletion in the Sarm1 AGS3 allele was evident by PCR of Sarm1 genomic DNA (Fig S2B,  206 left). The 13 b.p. deletion in the Sarm1 AGS12 allele was too small to be detected on an agarose gel, but 207 was detected using the Surveyor Nuclease assay (S2B, right). The guide sequence used for Sarm1 208 cleavage was high scoring and no potential off-target sites were present with less than 4 mismatches, 209
making CRISPR cleavage at off-target sites unlikely (30). Nonetheless, we tested 5 potential off-target 210 sites located in exonic regions that could potentially affect these genes. We did not detect cleavage 211 events at any of these sites as determined by the Surveyor Nuclease assay ( Fig S2C) . 212 213 
227
The Sarm1 AGS3 and Sarm1 AGS12 lines were breed to homozygosity creating two new Sarm1 knockout 228 strains. We compared responses of macrophages derived from WT, the original Sarm1 AD line, and the 229 Sarm1 AGS3 line. As expected, the Sarm1 AD macrophages showed defects in the production of Ccl3, Ccl4, 230 and Ccl5 mRNA in response to LPS (Fig 5A, top) or TNF-α ( Fig 5A, bottom) . However, the Sarm1 AGS3 line 231 showed responses comparable to WT. The Sarm1 AGS12 line also showed Ccl3, Ccl4, and Ccl5 responses 232 comparable to WT in response to TNF-α ( Fig 5B) . This shows that defects in the production of 233 chemokines in the original Sarm1 AD macrophages were due to background effects, and not SARM1 234 protein expression. 235 236
Sarm1 CRISPR knockout mice are protected from axonal degeneration 237 We have been unable to detect the expression of a SARM1-specific band by western blot using a number 238 of commercial antibodies and western blotting conditions (not shown). We therefore sought to confirm 239 knockout of SARM1 protein expression functionally in an axonal degeneration assay. For this purpose, 240
we performed sciatic nerve transections of the right hindlimb in WT and Sarm1 AGS3 mice. 14 days 241
following transection, WT mice showed breakdown of the axon and myelin sheath, while Sarm1 AGS3 mice 242 showed remarkable protection ( Fig 5C) as described previously in the Sarm1 AD strain (2). This confirms a 243 role for SARM1 in axonal degeneration, and functional knockout of SARM1 in the Sarm1 AGS3 line. 
254
Viral phenotypes of Sarm1 CRISPR mice 255 We had previously reported that Sarm1 AD mice are resistant to lethal encephalitic disease caused by VSV 256
infection (17). In order to determine if this was a true function of SARM1, we infected Sarm1 AGS3 and 257
Sarm1 AGS12 mice with VSV and monitored survival. As shown in Figure 6A , Sarm1 AD mice, but not 258 Sarm1 AGS3 or Sarm1 AGS12 mice were protected from VSV, suggesting that SARM1 does not play a role in 259 VSV infection. Our reported defects in cytokine and chemokine production in the brain of VSV-infected 260 mice were also due to background effects and not SARM1 protein ( Fig 6B) . An independent line of 261 SARM1-deficient mice (referred to here as Sarm1 MSD ) was generated in the Diamond lab also on the 129 262 background but lacking the neomycin cassette. These mice showed increased susceptibility to WNV 263 infection (15) . When Sarm1 AGS3 mice were infected with WNV, they were more susceptible than WT mice 264 ( Fig 6C) confirming a role for SARM1 in WNV infection in agreement with the Diamond study. 265
Surprisingly, Sarm1 AD mice showed similar susceptibility to WT mice to WNV infection ( Fig 6C and Table  266 I), suggesting that background effects in Sarm1 AD mice may have compensated for the impact of SARM1-267 deficiency on susceptibility to WNV infection. Sarm1 MSD mice were also reported to be protected from 268
LACV infection (16). When Sarm1 AD , Sarm1 AGS3 , and Sarm1 AGS12 mice were infected with LACV, all 269 strains showed similar susceptibility to WT mice, suggesting that SARM1 also does not play a role in 270 susceptibility to LACV infection ( Fig 6D) . 271 272 273 
281
The Sarm1 AD mice used in this study were backcrossed 10 times to the B6 background; Sarm1 MSD were 282
reported to be backcrossed to the B6 background, however the extent of backcrossing was not reported. 283
In order to determine the precise backgrounds of the two strains, we performed a 384 panel SNP 284 analysis. The Sarm1 AD mice were 99.5% B6, while the Sarm1 MSD mice were 94.6% B6. The Sarm1 AD 285 mice were found to differ from B6 at the expected location on chromosome 11 and one other region on 286 chromosome 10. The Sarm1 MSD mice were found to differ from B6 at multiple locations including large 287 portions of chromosome 10 and 11 (Table S1) , which may account for the different phenotypes observed 288 with the two strains. It should be noted that the precise genetic background of the strains used in different 289 labs and studies will likely differ depending on the extent of backcrossing done in individual labs. 290 291 Xaf1 expression differences are due to sequence and isoform polymorphism between B6 and 129 296
Significant differences in transcript levels of Xaf1, a proapoptotic protein, were reported by us in the 297
original Sarm1 AD strain both in the presence and absence of VSV infection, and others (20) in the 298 Sarm1 MSD strain both in the presence and absence of prion infection. Additionally, Xaf1 was the most 299 highly upregulated transcript in SARM1-deficient mice compared to WT mice in both studies. Two curated 300 protein-coding transcripts for Xaf1 have been described in mouse ( Fig 7A) , as well as a number of 301 predicted transcripts. Isoform 1 contains exons 1-6 and isoform 2 contains exons 1, 2, 5, and 6. The Xaf1 302 gene is also located in close proximity to the Sarm1 gene on chromosome 11 ( Fig 3A) . Alignment of 303
RNAseq reads from the Sarm1 AD strain to the B6 reference genome showed a number of nucleotide 304 differences ( Fig 7B -indicated by colored lines) , and the Sarm1 AD consensus sequence matched the 305 reported sequence for 129. The nucleotide differences in exons 4 and 5 result in 4 amino acid 306 substitutions ( Fig 7E) . The 129 sequence has a gap in the alignment at the 3' end of exon 6, which is the 307 result of a 248 bp deletion, and a large peak in the 3' UTR that is not present in B6. The deletion spans 308 the B6 stop codon and 2 polyadenylation sites, which likely results in a transcript that terminates much 309 later in 129, potentially effecting transcript stability. The 129 transcript uses an alternative stop codon 310 located after the deletion, resulting in truncation of the last 3 amino acids at the C-terminus of the protein 311 ( Fig 7E) . 312
Sashimi plots visualizing splice junctions showed an increase in junctions between exon 2 and 5 (10% to 313 48%) indicating less full length transcript in the Sarm1 AD strain, as well as a large increase in a novel 314 splice variant between exon 5 and 6 (4% to 30%) in the Sarm1 AD strain ( Fig 7C) . Using RT-PCR primers 315 directed against exon 1 and either the B6 or 129 exon 6, we detected the reported sequences for 316 transcripts 1 and 2 in B6 (Fig 7D and see table III for sizes and accession numbers). In 129 we detected 317 the reported sequence for transcript 1. The 3' end of the 129 transcript 2 was incomplete in databases, 318
and ended in the same sequence as transcript 1, resulting in the same C-terminal truncation. In the 129 319 samples we also detected two novel isoforms corresponding to the novel splice site between exon 5 and 320 6, leading to a novel long isoform (600 bp) similar to transcript 1 but lacking part of exon 5, and a novel 321 short isoform (315 bp) similar to transcript 2 but also lacking part of exon 5. We detected a band of similar 322 size to the novel long isoform in B6 ( Fig 7E -indicated by *) , however sequence analysis indicated this 323 was a 626 bp transcript lacking exon 3 and leading to early truncation of the protein. The alternative 324 splice site in exon 5 results in a large deletion of exon 5 ( Fig 7E) , but in-frame translation of exon 6. 325
Importantly, the C-terminal domain is thought to be essential for binding to XIAP (31), and short isoforms 326 are thought to function as dominant negative (22, 23) , suggesting that these strain differences may lead 327 to functional changes in XAF1. 328 329 
331
In order to test XAF1 antibodies, we generated XAF1-deficient 3T3 cell lines using CRISPR. Despite the 332 presence of non-specific bands, using one of these antibodies we could detect XAF1 expression 333 specifically in WT but not Xaf1 -/cells ( Fig S3) . This band was only present following IFN treatment, in 334 agreement with Xaf1 being an interferon-stimulated gene. Importantly, the antibody epitope is present in 335 all isoforms. Following treatment of mice with i.v. PIC to induce IFN, we were unable to detect XAF1 336 expression in the brain, but did observe expression in response to PIC treatment in the spleen. We 337 observed a band corresponding to the size of the full-length protein in WT, Sarm1 AD , and Sarm1 AGS3 338 mice. However, we also observed a unique band in the Sarm1 AD strain following PIC treatment, which 339 may represent either increased expression of isoform 2 or one of the novel isoforms ( Fig 7F) . No 340 differences in Xaf1 expression levels were observed between WT and Sarm1 AGS3 by RNAseq (Table IV) , 341
suggesting that SARM1 likely does not control XAF1 expression. Given the differential expression of 342 XAF1 in the Sarm1 AD strain, and its known role in cell death, we speculate that XAF1 may account for 343 some of the phenotypes described in this strain. 344 345
RNAseq on Sarm1 CRISPR mice 346
In order to understand possible functions for SARM1 we performed RNAseq on brainstem isolated from 347
WT and Sarm1 AGS3 mice infected with WNV or mock infected. In infected animals 9 transcripts were 348 differentially regulated (Table IV) . In mock infected animals 16 transcripts were differentially regulated, 4 349 of which are involved in the mitochondrial electron transport chain -Ndufa3 and Ndufb3 (complex I), 350
Uqcrh (complex III), and Atp5k (complex V), as well as a number of small and large ribosomal proteins, 351
and an apoptosis-associated tyrosine kinase (Table V and Fig 7D) . In agreement with this data, a recent 352 report suggests a role for SARM1 in mitochondrial respiration (8). plays a role outside of neural cells has proved difficult to answer. Studies on the expression and function 379 of SARM1 have been hampered by the lack of reliable antibodies, making it difficult to gauge whether 380 cells of the immune system express detectable protein levels. At the RNA level, evidence suggests 381 predominant expression of SARM1 in the CNS. However, it remains possible that cells in the periphery 382 express SARM1. We and others (15) did not detect the expression of SARM1 at the RNA level in 383 macrophages, using primers that span exons 7 and 8, and detect high expression in WT but not Sarm1 AD 384 brain. However, others report expression of a shorter 724 a.a. isoform in T cells and macrophages using 385 primers spanning exons 5-7 (18, 32) . Our primers should detect both isoforms, so the reason for the 386 discrepancy is unclear. 387 388
In this study, we sought to address whether SARM1 plays a role in macrophages using cells from 389
Sarm1 AD mice. Similar to published reports (18) we found differences in the production of Ccl5, as well as 390
Ccl3 and Ccl4 in Sarm1 AD macrophages. However, a number of lines of evidence support that this is not 391 due to SARM1 protein expression, but rather is due to background effects of the knockout strain. First, 392
the defect in Sarm1 AD macrophages is limited to 3 particular chemokine genes that are located in close 393 physical proximity to each other and the modified locus. Second, the defect is evident in response to a 394 wide array of stimuli that induce different signaling pathways. Third, we could find no defects in the 395 signaling components that are shared between the induction pathways for these stimuli. Fourth, siRNA 396 knockdown failed to reproduce the Sarm1 AD chemokine phenotype suggesting a lack of dependence on 397 SARM1 protein expression. Overexpression of SARM1 has been reported to modestly induce Ccl5 398 expression (18), however we were unable to reproduce these findings. Additionally, we found differences 399 in baseline expression of Ccl3, Ccl4, and Ccl5 in unstimulated macrophages from Sarm1 AD mice, 400 supporting an intrinsic difference. Finally, generation of new knockout strains on a pure genetic 401 background also failed to support a role for SARM1 in macrophage chemokine production. These data in 402 combination with the lack of expression/low expression of SARM1 in macrophages fail to support a role 403 for SARM1 as a TLR adaptor protein in myeloid cells. 404 405
A variety of both protective and detrimental effects have been reported in different infection models in 406 SARM1-deficient strains. These results are difficult to reconcile given the different construction of the 407 knockout strains, and the significant variation in genetic background. Additionally, studies have not 408
reported SNP analysis and whether or not additional backcrossing was done. SARM1 was reported to 409 have a negative effect on susceptibility to both VSV and LACV infection, while it was reported to have a 410 positive effect on susceptibility to WNV infection. We reported that Sarm1 AD mice were less susceptible to 411 VSV, and showed lower cytokine responses and infiltration in the brain, while Mukherjee et al reported 412
that Sarm1 MSD mice were protected from LACV infection, in a mechanism dependent on SARM1 413 interaction with MAVS (16). Our CRISPR knockout strains did not support a role for SARM1 in mediating 414 this effect in either infection model. Surprisingly, none of our knockout lines -including Sarm1 AD , 415
Sarm1 AGS3 , and Sarm1 AGS12 showed a protective effect during LACV infection, suggesting that the 416 phenotype is specific to either the Sarm1 MSD strain or the viral strain. We found the Sarm1 MSD strain to 417 differ from B6 at large portions of chromosome 10 and 11 in our analysis, which could account for the 418 discrepant results. Additionally, the LACV original strain was used in our study, while Mukherjee et al 419 used the LACV 1978 strain. These strains share 99% amino acid identity and are both highly virulent in 420 young mice (33, 34), however differences in pathogenesis are observed in some strains (35). Our 421 CRISPR knockout strains did, however support a role for SARM1 in mediating the positive effect during 422 WNV infection. Surprisingly, the Sarm1 AD line showed similar susceptibility to WT mice during WNV 423
infection. Both the Sarm1 AD and Sarm1 MSD lines were made on the 129 background, however the 424 Sarm1 AD line retains neomycin. Similar phenotypes in Sarm1 AGS3 , Sarm1 AGS12 , and Sarm1 MSD mice 425
suggest that either neomycin effects on neighboring genes, or other 129 background effects account for 426 the different phenotype of the Sarm1 AD strain to WNV. 427 428
Here we show background strain-dependent differences in the expression of the proapoptotic protein 429 XAF1, which may represent a good candidate gene for the protective effect described in the knockout 430 strains, however a number of other possibilities are consistent with the data. The protective phenotype 431 could be due to: 1) differences in chemokine levels due to the 129 congenic locus, which can also 432 influence immune cell infiltration 2) transcriptional interference from neomycin effecting chemokines or 433 other neighboring genes within the congenic interval 3) other mutations within the congenic interval or 4) 434 other background effects. We had originally reported that Sarm1 AD mice had lower levels of monocyte 435 and macrophage infiltration into the brain, in agreement with their lower cytokine/chemokine levels, and 436 postulated that this may lead to protection from immune-mediated tissue damage (17) day 5 post-infection. RNA preparation and sequencing was performed as above except that sequencing 716 was non-directional and used a NextSeq machine with 150 bp reads. Protein-protein association 717 networks were determined using STRING database (42). RNAseq datasets have been deposited in GEO 718 under the record numbers GSE136221 and GSE136284, and Xaf1 transcripts have been deposited in 719
Genbank under the accession number (submitted). 720 721
Sciatic nerve transections 722
WT and Sarm1 AGS3 were anesthetized with ketamine/xylazine, fur was shaved, and skin was cleaned. An 723 incision was made in the skin and the muscle was separated to expose the sciatic nerve. A 1 mm portion 724 of the nerve was excised, and the skin was closed with staples. Antibiotic ointment was applied to the 725 incision and 0.05 mg/kg buprenorphine was administered immediately and at 6 hrs for pain. Mice were 726 housed for 14 days, and euthanized with 15% aqueous choral hydrate, followed by perfusion with 1% 727
Paraformaldehyde/PBS, pH 7.2 at a flow rate of 7.5 mls/min, and immediately with 2% paraformaldehyde 728 and 2% glutaraldehyde/PBS, pH 7.2 at the same flow rate for an additional 10 minutes. Skin was 729 removed, and the carcass placed in immersion fixation (same as above) to be post-fixed for a minimum of 730 one week at 4 degrees C. The transected and non-transected nerves were removed and 731 flat mold embedded to ensure cross-sectional orientation in EPON resin. Polymerized blocks were 732 sectioned on a Leica UC7 Ultramicrotome using a histoknife at 0.5 um, counterstained with 1% Toluidine 733
Blue and coverslipped. Brightfield images were acquired with an Axioimager Z2M microscope (Zeiss) with 734 an EC Plan-Neofluar 40x/1.3 oil objective, and processed with Fiji software (NIH 
